Skip to Main content Skip to Navigation
Journal articles

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience

Abstract : The optimal management of patients with relapsed chronic lymphocytic leukemia (CLL) is dictated by the type of prior therapy, duration of prior response, presence of genomic aberrations, age, and comorbidities. The patterns of relapses and the clinical outcomes of second-line options after fludarabine-cyclophosphamide-rituximab (FCR) is given as a frontline treatment are currently unknown. In this retrospective and non-randomized study, we report the outcomes of 132 patients from databases of 14 French CLL study group centers who needed a second-line treatment after FCR frontline. Bendamustine + rituximab (BR) was the most frequently used second-line regimen, followed by alemtuzumab-based regimens, R-CHOP, and FCR. Median progression-free survival (PFS) was 18 months after BR with a median overall survival (OS) not reached. We also found that response durations of < 36 months and the presence of del(17p) are critical factors that contribute to poor overall survival. BR appears to be an effective salvage regimen in our series, both in terms of progression-free and overall survival. Patients who relapsed less than 36 months after FCR have a poor outcome, not significantly different in this study from patients with early relapses less than 12 or 24 months.
Document type :
Journal articles
Complete list of metadatas

https://hal.univ-lorraine.fr/hal-01684650
Contributor : Ngere Ul <>
Submitted on : Monday, January 15, 2018 - 4:40:47 PM
Last modification on : Friday, February 19, 2021 - 5:00:02 PM

Identifiers

Citation

Luc-Matthieu Fornecker, Thérèse Aurran-Schleinitz, Anne-Sophie Michallet, Bruno Cazin, Romain Guiéze, et al.. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: The French intergroup experience. American Journal of Hematology, Wiley, 2015, 90 (6), pp.511 - 514. ⟨10.1002/ajh.23999⟩. ⟨hal-01684650⟩

Share

Metrics

Record views

292